Comparison of 3D and 2D tumor models reveals enhanced HER2 activation in 3D associated with an increased response to trastuzumab

Oncogene

Volumn 28, Issue 3, 2009, Pages 461-468

  Pickl, M ^a   Ries, C H ^a  

^a ROCHE DIAGNOSTICS GMBH   (Germany)

Author keywords

3D cell culture; HER2 signaling; Membrane raft; Trastuzumab

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; INTEGRIN; MITOGEN ACTIVATED PROTEIN KINASE; MONOCLONAL ANTIBODY; P21 ACTIVATED KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; RAC1 PROTEIN; RAC1 PROTEIN, HUMAN; TRASTUZUMAB;

ARTICLE; BREAST TUMOR; CELL MEMBRANE; CELL PROLIFERATION; CELL SURVIVAL; CULTURE TECHNIQUE; DIMERIZATION; DRUG EFFECT; HUMAN; METABOLISM; MULTICELLULAR SPHEROID; PATHOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL CULTURE;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL CULTURE TECHNIQUES; CELL PROLIFERATION; CELL SURVIVAL; DIMERIZATION; HUMANS; INTEGRINS; MEMBRANE MICRODOMAINS; MITOGEN-ACTIVATED PROTEIN KINASES; P21-ACTIVATED KINASES; RAC1 GTP-BINDING PROTEIN; RECEPTOR, ERBB-2; SIGNAL TRANSDUCTION; SPHEROIDS, CELLULAR; TUMOR CELLS, CULTURED;

EID: 59649109230     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2008.394     Document Type: Article

References (32)

1. Engelman JA, Lee RJ, Karnezis A, Bearss DJ, Webster M, Siegel P et al. (1998). Reciprocal regulation of neu tyrosine kinase activity and caveolin-1 protein expression in vitro and in vivo. Implications for human breast cancer. J Biol Chem 273: 20448-20455.
2. Guo H, Wei B, Zhang HY, Liu GJ, Bu H, Lang ZQ et al. (2005). [HER2 expression and its prognostic implication in lymph node negative breast carcinoma: a meta-analysis]. Zhonghua Bing Li Xue Za Zhi 34: 140-146.
3. Hudis CA. (2007). Trastuzumab-mechanism of action and use in clinical practice. N Engl J Med 357: 39-51.
4. Hudziak RM, Lewis GD, Winget M, Fendly BM, Shepard HM, Ullrich A. (1989). p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor. Mol Cell Biol 9: 1165-1172.
5. Jung J-H, Traugh JA. (2005). Regulation of the interaction of Pak2 with Cdc42 via autophosphorylation of serine 141. J Biol Chem 280: 40025-40031.
6. Kwon T, Kwon DY, Chun J, Kim JH, Kang SS. (2000). Akt protein kinase inhibits Rac1-GTP binding through phosphorylation at serine 71 of Rac1. J Biol Chem 275: 423-428.
7. Lee GY, Kenny PA, Lee EH, Bissell MJ. (2007). Three-dimensional culture models of normal and malignant breast epithelial cells. Nat Methods 4: 359-365.
8. Longva KE, Pedersen NM, Haslekås C, Stang E, Madshus IH. (2005). Herceptin-induced inhibition of ErbB2 signaling involves reduced phosphorylation of Akt but not endocytic down-regulation of ErbB2. Int J Cancer 116: 359-367.
9. Miljan EA, Bremer EG. (2002). Regulation of growth factor receptors by gangliosides. Sci STKE 2002: RE15.
10. MocanuM-M, Fazekas Z, Petrás M, Nagy P, Sebestyén Z, Isola J et al. (2005). Associations of ErbB2, β1-integrin and lipid rafts on Herceptin (Trastuzumab) resistant and sensitive tumor cell lines. Cancer Lett 227: 201-212.
11. Nagy P, Vereb G, Sebestyén Z, Horváth G, Lockett SJ, Damjanovich S et al. (2002). Lipid rafts and the local density of ErbB proteins influence the biological role of homo-and heteroassociations of ErbB2. J Cell Sci 115: 4251-4262.
12. Nahta R, Esteva FJ. (2006). Herceptin: mechanisms of action and resistance. Cancer Lett 232: 123-138.
13. Owens MA, Horten BC, Da Silva MM. (2004). HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues. Clin Breast Cancer 5: 63-69.
14. Petersen OW, Rønnov-Jessen L, Howlett AR, Bissell MJ. (1992). Interaction with basement membrane serves to rapidly distinguish growth and differentiation pattern of normal and malignant human breast epithelial cells. Proc Natl Acad Sci USA 89: 9064-9068.
15. Pike LJ. (2006). Rafts defined: a report on the Keystone symposium on lipid rafts and cell function. J Lipid Res 47: 1597-1598.
16. Razani B, Schlegel A, LiuJ, Lisanti MP. (2001). Caveolin-1, a putative tumour suppressor gene. Biochem Soc Trans 29: 494-499.
17. Ritter CA, Perez-Torres M, Rinehart C, Guix M, Dugger T, Engelman JA et al. (2007). Human breast cancer cells selected for resistance to trastuzumab in vivo overexpress epidermal growth factor receptor and ErbB ligands and remain dependent on the ErbB receptor network. Clin Cancer Res 13: 4909-4919.
18. Schoenwaelder SM, Burridge K. (1999). Bidirectional signaling between the cytoskeleton and integrins. Curr Opin Cell Biol 11: 274-286.
19. Shaw KRM, Wrobel CN, Brugge JS. (2004). Use of three-dimensional basement membrane cultures to model oncogene-induced changes in mammary epithelial morphogenesis. J Mammary Gland Biol Neoplasia 9: 297-310.
20. Shin S-I, Freedman VH, Risser R, Pollack R. (1975). Tumorigenicity of virus-transformed cells in nude mice is correlated specifically with anchorage independent growth in vitro. Proc Natl Acad Sci USA 72: 4435-4439.
21. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE et al. (1989). Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244: 707-712.
22. neu. Biochim Biophys Acta 1635: 55-66.
23. Sottocornola E, Misasi R, Mattei V, Ciarlo L, Gradini R, Garofalo T et al. (2006). Role of gangliosides in the association of ErbB2 with lipid rafts in mammary epithelial HC11 cells. FEBS J 273: 1821-1830.
24. Timms JF, White SL, O'Hare MJ, Waterfield MD. (2002). Effects of ErbB-2 overexpression on mitogenic signalling and cell cycle progression in human breast luminal epithelial cells. Oncogene 21: 6573-6586.
25. Wang SC, Hung MC. (2001). HER2 overexpression and cancer targeting. Semin Oncol 28: 115-124.
26. Weaver VM, Lelièvre S, Lakins JN, Chrenek MA, Jones JCR, Giancotti F et al. (2002). β4 integrin-dependent formation of polarized three-dimensional architecture confers resistance to apoptosis in normal and malignant mammary epithelium. Cancer Cell 2: 205-216.
27. Wolff AC, Hammond MEH, Schwartz JN, Hagerty KL, Allred DC, Cote RJ et al. (2007). American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 25: 118-145.
28. Yakes FM, Chinratanalab W, Ritter CA, King W, Seelig S, Arteaga CL. (2002). Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt is required for antibody-mediated effects on p27, cyclin D1, and antitumor action. Cancer Res 62: 4132-4141.
29. Yamada KM, Cukierman E. (2007). Modeling tissue morphogenesis and cancer in 3D. Cell 130: 601-610.
30. Yarden Y. (2001). The EGFR family and its ligands in human cancer: signalling mechanisms and therapeutic opportunities. Eur J Cancer 37(Suppl 4): S3-S8.
31. Yaziji H, Goldstein LC, Barry TS, Werling R, Hwang H, Ellis GK et al. (2004). HER-2 testing in breast cancer using parallel tissuebased methods. JAMA 291: 1972-1977.
32. ZhouX, Tan M, Hawthorne VS, Klos KS, Lan KH, Yang Y et al. (2004). Activation of the Akt/mammalian target of rapamycin/4EBP1 pathway by ErbB2 overexpression predicts tumor progression in breast cancers. Clin Cancer Res 10: 6779-6788.